This analysis demonstrates potent antitumour activity in B cell lymphoma using bispecific CAR-T cells, highlighting promising preclinical evidence for dual-targeting approaches.
Key Points
Bispecific CAR-T therapy targeting CD79b and CD19 showed powerful antitumour activity against B-cell lymphoma.
Four CAR constructs were engineered, exhibiting significant antitumor efficacy in both in vitro and in vivo models.
Functional characterization measured through cytotoxicity assays indicated robust responses in malignant B-cell lymphoma cells.
These findings indicate a strong potential for clinical advancement of dual-targeting CAR-T cell therapies against lymphoma.